Inclusion Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

- For fever control and mild analgesia, modest doses of aspirin or nonprescription
doses of ibuprofen may be used with caution; prolonged (> 72 hours) administration is
not advised without dose supervision.

Patients must have a documented history of positive HIV antibody by ELISA, or positive
result by ELISA at study entry and be in one of the following categories:

- AIDS patients recovered from one or more episodes of categorically confirmed
Pneumocystis carinii pneumonia (PCP) who were previously enrolled in the zidovudine
(AZT) treatment IND protocol.

- Patients who qualify for AZT under the labeling:

- (a) patients with a prior episode of cytologically confirmed PCP; (b) patients with a
prior episode of any other AIDS defining opportunistic infection and < 200 T4 cells;
(c) patients with advanced AIDS related complex (ARC) as defined by the clinical
diagnosis of mucocutaneous candidiasis and/or unexplained weight loss (= or > 15 lbs
or > 10 percent of total body weight within the previous 3 months) and < 200 T4 cells
and one or more of the following symptoms:

- (1) fever > 100 degrees F without infectious cause of > 3 weeks duration; (2)
clinical diagnosis of hairy leukoplakia; (3) herpes zoster infection within 3 months
of entry; (4) unexplained diarrhea after 3 samples eliminating ova, parasites,
cryptosporidia, and Mycobacterium avium-intracellulare.

Note:

- Kaposi's sarcoma without any of the symptoms listed above, regardless of total T4
lymphocyte count, does not constitute an indication for AZT treatment under the
labeling.

Exclusion Criteria

Co-existing Condition:

- Patients whose symptoms do not fit into the categories described in Disease Status
and General Inclusion Criteria are excluded.

Concurrent Medication: Excluded:

- Acetaminophen.